

Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization

### ASMS 2017 ThP-086

Marc FERNANDEZ<sup>1</sup>, Aurore JAFFUEL<sup>1</sup>, Fanny DAYOT<sup>2</sup>, Jean-François HOEFFLER<sup>2</sup>, Alban HUTEAU<sup>1</sup> 1. SHIMADZU France, le Luzard II, bat A, Bd Allende, Noisiel, 77448 Marne La Vallée cedex 2, France, 2. ALSACHIM, 160 Rue Tobias Stimmer, 67400 Illkirch, France



PO-CON1773E

Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization

## Introduction

Measurement of immunosuppressant drugs (Figure 1.) is essential during organ transplantation. Under-dosing can lead to organ rejection, while over-dosing can cause serious toxicity. Traditional methods to measure immunosuppressant drugs in whole blood are based on either immunoassays or chromatography. Immunoassays, though, are affected by matrix interferences and lack of specificity. LC-MS/MS has then become the gold standard due to its specificity, precision and sensitivity. However, it has still one major drawback: current LC-MS/MS platforms demand personnel with expertise and, for whole blood samples, tedious sample preparation. As a consequence, sample throughput is generally much lower than for immunoassays. We here report a fully automated procedure for the quantitation of four major immunosuppressant in whole blood samples, using of 13C labelled internal standards.




Figure 1. Structures of tacrolimus (a), sirolimus (b), everolimus (c), and cyclosporine-A (d)

# Methods and Materials

The quantitative analysis of Immunosuppressant (Figure 2.) was performed using reagents provided in Alsachim Dosimmune<sup>®</sup> kit. The Immunosuppressant and Internal standard were monitored using UHPLC-MS/MS system (Nexera X2 and LCMS-8050, Shimadzu, Kyoto). Sample preparation was performed using extraction buffer and

internal standard set provided in Alsachim Dosimmune<sup>®</sup> kit. Analytical performance of the method was monitored using whole blood calibrators and whole blood QC. Automatic sample preparation was performed using CLAM-2000 module (Shimadzu, Kyoto).



Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization



Figure 2. Sample workflow overview.

#### Sample preparation : CLAM-2000 and Dosimmune® kit

Whole blood sample tube is placed into the CLAM-2000 system : (1)  $25\mu$ L of whole blood sample is mixed with 12.5 $\mu$ L of Internal standard and 175 $\mu$ L of extraction buffer solution, (2) followed by a 30s stirring and (3) a 1min filtration. The extracted sample is transferred to the autosampler of the Nexera X2 system and injected immediately.

UHPLC conditions	: Nexera X2 and Dosimmune® kit
Analytical column	: Ascentis <sup>®</sup> C18 2,1x50 mm, 5 μm
Trap column	: Ascentis ® C8 4,6x30 mm, 5 µm
Injection volume	: 20 µL
Mobile Phase A	: 90% 3mM Ammonium formate (pH=3.6) 10% MeOH
Mobile Phase B	: 10% 3mM Ammonium formate (pH=3.6) 90% MeOH
Isocratic flow rate	: Mobile Phase A: 2 mL/min (trap column),
	Mobile Phase B: 0.8 mL/min (analytical column)
Oven temperature	: 65°C
MS conditions	: LCMS-8050
Nebulizing Gas	: 3 L/min (N <sub>2</sub> )
Heating Gas	: 10 L/min (Air)
Drying Gas	: 10 L/min (N <sub>2</sub> )
HESI	: 200°C
DL	: 250°C
HB	: 200°C
Pause time	: 1 msec
Polarity switching	: 5 msec
Points per peak	: > 30

Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization

Compound	Formula	Exact Mass	MRM
Evérolimus	C <sub>53</sub> H <sub>83</sub> NO <sub>14</sub>	957,6	975,6 → 908,5
Evérolimus <sup>13</sup> C <sub>2</sub> d <sub>4</sub>	C <sub>51</sub> <sup>13</sup> C <sub>2</sub> H <sub>79</sub> D <sub>4</sub> NO <sub>14</sub>	963,6	981,5 → 914,5
Sirolimus	C <sub>51</sub> H <sub>79</sub> NO <sub>13</sub>	913,5	931,6 → 864,5
Sirolimus <sup>13</sup> Cd <sub>3</sub>	C <sub>50</sub> <sup>13</sup> CH <sub>76</sub> D <sub>3</sub> NO <sub>13</sub>	917,5	935,4 → 864,5
Tacrolimus	C <sub>44</sub> H <sub>69</sub> NO <sub>12</sub>	803,5	821,5 → 768,6
Tacrolimus <sup>13</sup> Cd <sub>4</sub>	C <sub>43</sub> <sup>13</sup> CH <sub>67</sub> D <sub>4</sub> NO <sub>12</sub>	808,5	826,4 → 773,6
Ciclosporine	C <sub>62</sub> H <sub>111</sub> N <sub>11</sub> O <sub>12</sub>	1201,8	1219,9 → 1202,8
Ciclosporine d <sub>12</sub>	C <sub>62</sub> H <sub>99</sub> D <sub>12</sub> N <sub>11</sub> O <sub>12</sub>	1213,8	1231,8 → 1214,9

Table 1. Formula, exact mass and MRM transition for each compound.

# Results

### Method conditions

The method enables the quantification of tacrolimus, sirolimus, everolimus and cyclosporine-A in whole blood samples. The established quantification strategy for this compounds is to use internal calibration using deuterium labeled standards. However, they generally suffer from poor isotopic enrichment, leading to overestimation of the unlabeled form. We here use 13C labeled internal standards for tacrolimus, sirolimus and everolimus. This guaranties better isotopic enrichment, better precision of the results, long term stability of the standards and perfect co-elution with the analytes, leading to a better correction of matrix effects. Linearity was confirmed in the range 0.5 to 40 ng/mL for tacrolimus, sirolimus, everolimus, and in the range 5 to 1500 ng/mL for cyclosporine-A (Figure 3.). For all analytes, r<sup>2</sup> of linearity models was above 0.99, with S/N > 25 for LLOQ levels (Figure 4.). Controls showed accuracies comprised in between 85 and 115% for all analytes (Table 2.).

### Excellence in Science Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization

### Calibration in whole blood

Linearity was confirmed, in whole blood, in the range 0.5-40 ng/mL for tacrolimus (Figure 3.a.), sirolimus (Figure 3.b.), everolimus (Figure 3.c.), and 5-1500 ng/mL for cyclosporine-A (Figure 3.d.).




Figure 3. Calibration curves for tacrolimus (a), sirolimus (b), everolimus (c), and cyclosporine-A (d), in whole blood.

### Limits of quantification in whole blood

The limits of quantification (LLOQ), in whole blood, are 0.5 ng/mL for tacrolimus, sirolimus, and everolimus, and 5 ng/mL for cyclosporine-A. The signal to noise ratio is above 25 at LLOQ levels.




Figure 4. MRM chromatograms, at LLOQ levels, for tacrolimus (a), sirolimus (b), everolimus (c), and cyclosporine-A (d), in whole blood.

Fully automated sensitive determination of immunosuppressant drugs in whole blood, using high quality internal standardization

#### Performance Evaluation

Whole blood controls showed accuracies comprised in between 85% and 115% for all analytes.

Table 2. Whole blood control samples accuracies.

Tacrolimus		
Conc. (µg/mL)	Accuracy (%)	
2.9	114	
5.4	108	
13.3	87	
40.5	95	

Everolimus		
Conc. (µg/mL)	Accuracy (%)	
3.2	114	
5.8	92	
13.4	85	
42.1	94	

Sirolimus		
Conc. (µg/mL)	Accuracy (%)	
3.2	115	
5.7	105	
13.3	93	
40.6	103	

Cyclosporine-A			
Conc. (µg/mL)	Accuracy (%)		
36.1	98		
223.4	106		
454.6	85		
1693	95		

## Novel Aspect

Fully automated sensitive quantification of immunosuppressant drugs in whole blood, using high quality 13C labelled internal standards, increasing data guality, throughput and safety.

For Research Use Only. Not for use in diagnostic procedures. Not available in the USA, Canada and China.

First Edition: June, 2017



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "@". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.